Oric selloff brings favorable entry point, says H.C. Wainwright

H.C. Wainwright says the share pullback on Ipsen (IPSEY) voluntarily withdrawing Tazverik from the market creates a favorable entry point for Oric Pharmaceuticals (ORIC). Oric’s rinzimetostat has a different mechanism of action is different from Tazverik, the analyst tells investors in a research note. H.C. Wainwright believes the increased risk of econdary malignancies may be specific to Tazverik and not a potential class-wide safety issue. It reiterates a Buy rating on Oric with a $25 price target